PBM PBM
Company Profile ↓Company Overview
PBM (PBM) is a publicly traded company listed on with a market capitalization of $7.54M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 0.1.
Recent Developments
- Trailing 12 Months Year-on-year growth — earnings -785.6%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -785.56% |
Stock Price Performance
| 1 Year: | -98.14% |
| 6 Months: | +6.47% |
| 3 Months: | -46.15% |
| 1 Month: | +5.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)54.17 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 98.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | - |
| Gross Profit | - |
| Operating Expenses | 1.51M |
| Operating Income | -1.51M |
| EBITDA | -749.17K |
| Interest Expense | 2.75K |
| Pretax Income | -753.25K |
| Tax Provision | - |
| Net Income | -753.25K |
| Diluted EPS | -3.19 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 3.23M | 43.35M | 3.66M | 5.95M |
| Operating Income | - | -3.23M | -43.35M | -3.66M | -5.95M |
| EBITDA | - | -3.21M | -51.11M | 1.03M | -6.92M |
| Interest Expense | - | 0 | 52.94K | 9.27K | 9.52K |
| Pretax Income | - | -3.21M | -51.16M | 1.01M | -6.94M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -3.21M | -51.16M | 1.01M | -6.94M |
| Diluted EPS | -544.78 | -940.02 | -14,274.29 | 32.76 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 1.59M | 1.13M | 7.32M | 17.57M |
| Current Assets | - | 1.59M | 1.13M | 6.56M | 9.11M |
| Cash & Equivalents | - | 1.33M | 733.19K | 6.14M | 7.44M |
| Inventory | - | - | - | - | - |
| Receivables | - | 149.37K | 41.75K | 137.35K | 362.76K |
| Total Liabilities | - | 1.79M | 12.10M | 594.37K | 623.19K |
| Current Liabilities | - | 1.79M | 12.10M | 594.37K | 623.19K |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | 10.45M | - | - |
| Total Equity | - | -200.44K | -10.97M | 6.72M | 16.94M |
| Shares Outstanding | - | 3.41K | 3.58K | 90.88K | 2.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -1.59M | -2.95M | -3.73M | -8.14M |
| Investing Cash Flow | - | 0 | -5.73K | -16.23K | -4.51M |
| Financing Cash Flow | - | 1.17M | 2.35M | 9.15M | 13.96M |
| Capital Expenditure | - | - | -5.73K | -9.88K | -500.23K |
| Free Cash Flow | - | -1.59M | -2.95M | -3.74M | -8.64M |
| Net Change in Cash | - | -419.16K | -601.09K | 5.40M | 1.31M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 1,599.6% | 466.2% | 15.1% | -40.9% |
| ROCE % | - | 1,613.8% | 395.1% | -54.5% | -35.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PBM
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical researc…
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Canopy Growth Refreshed Tweed Brand with Summer Campaign Push High Tide Announced Proactive Steps to Investigate and Address Suspected Share Trading Irregularities Key Takeaways; Psychedelic Sector Compass Pat…
FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain
Shares of some psychedelic drug companies gained Friday morning after the US Food and Drug Administr
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site networkNEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMe…
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chainNEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or …
Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness
Compass Pathways (CMPS) and other psychedelic shares were up in Monday premarket activity, after US
PBM — Frequently Asked Questions
What is the current share price of PBM?
As of 2026-08-05 17:25 PDT, PBM trades at $3.29 on NASDAQ/NYSE. Its 52-week range is $2.23 to $207.03.
What is the market capitalisation of PBM?
PBM has a market capitalisation of $7.54M on NASDAQ/NYSE.
What is the P/E ratio of PBM?
PBM trades at a trailing price-to-earnings (P/E) ratio of 0.10. Its price-to-book (P/B) ratio is 0.45.
What is the return on equity (ROE) of PBM?
PBM has a return on equity (ROE) of -40.94%. Its return on capital employed (ROCE) is -35.09%.
Is PBM a good stock to buy?
This page provides a data-driven analysis of PBM, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.